Literature DB >> 8126164

Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.

R Geertsen1, A Espander-Jansson, M Dobec, P Price, W Wunderli, L Rymo.   

Abstract

The baculovirus expression system was used to produce full-length Epstein-Barr virus nuclear antigens (EBNAs) 2A and 2B. Recombinant baculoviruses that contained the EBNA-2A- and EBNA-2B-encoding sequences were constructed. The proteins were expressed in Spodoptera frugiperda SF-9 cells infected with the recombinant viruses and were characterized by using monoclonal and human polyclonal antibodies by immunoblotting and immunofluorescence techniques. Partially purified extracts of the EBNA-2A- and EBNA-2B-infected insect cells were used to establish a new enzyme-linked immunosorbent assay for the detection of antibodies against EBNA-2A and EBNA-2B. Preferential reactivity toward the type A or type B EBNA-2 protein was observed in 36% of serum specimens from Swiss patients with acute infectious mononucleosis and in 81% of Swiss patients with latent Epstein-Barr virus infection. Of the patients in the latter group, sera from 76% reacted preferentially with EBNA-2A, sera from 5% reacted preferentially with EBNA-2B, sera from 12% showed similar reactivities against both antigens, and sera from 7% were nonreactive.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126164      PMCID: PMC262979          DOI: 10.1128/jcm.32.1.112-120.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  Longitudinal study of Epstein-Barr virus genotypes associated with infectious mononucleosis patients and healthy carriers.

Authors:  M L Lung; R S Chang
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

2.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

3.  Detection of a second widespread strain of Epstein-Barr virus.

Authors:  J W Sixbey; P Shirley; P J Chesney; D M Buntin; L Resnick
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

5.  The type-specific epitopes of the Epstein-Barr virus nuclear antigen 2 are near the carboxy terminus of the protein.

Authors:  D T Rowe; J R Clarke
Journal:  J Gen Virol       Date:  1989-05       Impact factor: 3.891

6.  Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis.

Authors:  A Linde; B Kallin; J Dillner; J Andersson; L Jägdahl; A Lindvall; B Wahren
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

7.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.

Authors:  T B Sculley; A Apolloni; L Hurren; D J Moss; D A Cooper
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

9.  High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors.

Authors:  V A Luckow; M D Summers
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

10.  Fragment length polymorphisms among independent isolates of Epstein-Barr virus from immunocompromised and normal hosts.

Authors:  B Z Katz; J C Niederman; B A Olson; G Miller
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.